|
Patent landscape, scope, and claims: |
United States Drug Patent 8,883,805: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 8,883,805, titled "Antipathogenic composition and method," was granted on November 10, 2014, to Alexion Pharmaceuticals, Inc. This patent claims a pharmaceutical composition comprising a combination of a lysosomotropic agent and an antibacterial agent. The primary therapeutic target described is bacterial infections, with a specific emphasis on Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). The patent asserts novelty and utility in enhancing the efficacy of antibacterial agents by facilitating their intracellular delivery and increasing intracellular concentrations. The patent landscape analysis reveals a competitive environment with other entities holding patents related to lysosomotropic agents, antibacterial compounds, and combination therapies for infectious diseases.
What Is the Core Invention Claimed in U.S. Patent 8,883,805?
The core invention claimed in U.S. Patent 8,883,805 is a pharmaceutical composition designed to treat bacterial infections. The composition is defined by the co-administration of two key components:
- A lysosomotropic agent: These are weak bases that accumulate in lysosomes, increasing their pH. Examples provided in the patent include chloroquine, hydroxychloroquine, amodiaquine, quinine, mefloquine, bupivacaine, and procaine.
- An antibacterial agent: This component targets and kills bacteria. The patent broadly covers various classes of antibacterial agents, including beta-lactams, macrolides, fluoroquinolones, tetracyclines, aminoglycosides, lincosamides, and sulfonamides.
The claimed method involves administering this combined composition to a subject in need of treatment for a bacterial infection. The mechanism of action proposed is that the lysosomotropic agent enhances the delivery and intracellular concentration of the antibacterial agent, thereby increasing its efficacy. The patent specifically highlights Staphylococcus aureus and MRSA as key targets.
What Are the Specific Claims Covered by the Patent?
U.S. Patent 8,883,805 comprises multiple claims, outlining the precise legal boundaries of the invention. These claims can be categorized as composition claims and method claims.
Composition Claims
The key composition claims define the specific formulations and combinations protected by the patent.
-
Claim 1: This is an independent claim and is central to the patent's scope. It defines a pharmaceutical composition comprising:
- A lysosomotropic agent.
- An antibacterial agent.
- A pharmaceutically acceptable carrier.
The claim further specifies that the lysosomotropic agent is one selected from the group consisting of chloroquine, hydroxychloroquine, amodiaquine, quinine, mefloquine, bupivacaine, and procaine. The antibacterial agent is described as an agent that exhibits antibacterial activity against Staphylococcus aureus.
-
Claim 2: This is a dependent claim that further narrows Claim 1. It specifies that the lysosomotropic agent is hydroxychloroquine.
-
Claim 3: Another dependent claim, specifying that the antibacterial agent is selected from the group consisting of a beta-lactam, a macrolide, a fluoroquinolone, a tetracycline, an aminoglycoside, a lincosamide, and a sulfonamide.
-
Claim 4: This dependent claim specifies that the antibacterial agent is selected from the group consisting of oxacillin, nafcillin, dicloxacillin, cefazolin, cephalexin, vancomycin, daptomycin, linezolid, erythromycin, azithromycin, clarithromycin, ciprofloxacin, levofloxacin, doxycycline, tetracycline, gentamicin, tobramycin, clindamycin, and sulfamethoxazole.
-
Claim 5: This dependent claim specifies that the antibacterial agent is an agent that exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
-
Claim 6: This dependent claim specifies that the lysosomotropic agent is present in an amount effective to increase the pH of a lysosome, and the antibacterial agent is present in an amount effective to inhibit or kill Staphylococcus aureus.
Method Claims
The method claims outline the specific therapeutic applications and administration procedures protected.
-
Claim 7: This independent claim covers a method of treating a bacterial infection in a subject. The method comprises administering to the subject:
- A lysosomotropic agent.
- An antibacterial agent.
- A pharmaceutically acceptable carrier.
Similar to Claim 1, the lysosomotropic agent is defined from a specific list, and the antibacterial agent exhibits activity against Staphylococcus aureus.
-
Claim 8: A dependent claim specifying that the lysosomotropic agent is hydroxychloroquine.
-
Claim 9: A dependent claim specifying the antibacterial agent is selected from a defined list of classes.
-
Claim 10: A dependent claim specifying the antibacterial agent is selected from a defined list of specific compounds.
-
Claim 11: A dependent claim specifying that the antibacterial agent is an agent that exhibits antibacterial activity against MRSA.
-
Claim 12: A dependent claim specifying that the method is for treating a Staphylococcus aureus infection.
-
Claim 13: A dependent claim specifying that the method is for treating an MRSA infection.
-
Claim 14: A dependent claim specifying that the lysosomotropic agent is administered in an amount effective to increase the pH of a lysosome, and the antibacterial agent is administered in an amount effective to inhibit or kill Staphylococcus aureus.
The patent further includes claims related to specific dosage regimens and combinations of agents, designed to cover various therapeutic scenarios. The broad language used for the antibacterial agent and its activity against Staphylococcus aureus and MRSA is a significant aspect of the patent's asserted scope.
How Does the Patent Address the Mechanism of Action?
The patent posits that the efficacy of antibacterial agents can be enhanced by co-administration with lysosomotropic agents through a mechanism that involves altering intracellular pH.
The proposed mechanism is as follows:
- Lysosomal Accumulation: Lysosomotropic agents, being weak bases, readily cross cell membranes in their unprotonated form. Once inside the acidic environment of lysosomes, they become protonated and trapped, leading to an accumulation within these organelles.
- Increased Lysosomal pH: The accumulation of these weak bases within lysosomes causes an increase in their internal pH, making the lysosomal environment less acidic.
- Enhanced Antibacterial Delivery and Concentration: Many bacteria, particularly intracellular pathogens or those residing within host cells, are susceptible to antibacterial agents. The patent suggests that by increasing lysosomal pH, the lysosomotropic agent can:
- Facilitate the uptake and transport of antibacterial agents into the cell.
- Increase the concentration of the antibacterial agent within intracellular compartments, such as lysosomes.
- Potentially disrupt bacterial defense mechanisms that rely on acidic environments.
- Improved Antibacterial Efficacy: The increased intracellular concentration and potentially altered cellular environment due to the lysosomotropic agent's action lead to a more potent and effective killing or inhibition of the target bacteria. The patent specifically highlights that this mechanism can overcome resistance mechanisms that may be present in certain bacterial strains.
The patent's disclosures include data from in vitro experiments demonstrating the increased intracellular accumulation of antibacterial agents in the presence of lysosomotropic agents and subsequent enhanced bacterial killing, particularly against S. aureus.
What Is the Asserted Utility and Target Indication?
The asserted utility of the invention described in U.S. Patent 8,883,805 is the treatment of bacterial infections. The patent places a significant emphasis on infections caused by Staphylococcus aureus, including drug-resistant strains.
Key target indications and applications include:
- Treatment of Staphylococcus aureus infections: This encompasses a wide range of infections caused by S. aureus, such as skin and soft tissue infections, pneumonia, bloodstream infections (bacteremia), and bone and joint infections.
- Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) infections: A primary focus is on overcoming the resistance mechanisms exhibited by MRSA, a major public health concern. The patent aims to provide a therapeutic option for infections caused by strains that are resistant to beta-lactam antibiotics.
- Enhancement of existing antibacterial therapies: The invention is presented as a way to improve the effectiveness of established antibacterial agents, potentially allowing for lower doses, reduced treatment durations, or improved outcomes in difficult-to-treat infections.
- Broad-spectrum applicability: While focusing on S. aureus, the claims are broad enough to potentially cover other bacterial infections where intracellular delivery or lysosomal targeting of antibacterial agents could be beneficial.
The patent’s disclosure supports these utilities with experimental data, illustrating the synergistic effect of combining lysosomotropic agents with specific antibacterial agents against S. aureus and MRSA.
What Is the Patent Landscape for Lysosomotropic Agents and Combination Therapies for Infection?
The patent landscape surrounding lysosomotropic agents and combination therapies for infectious diseases is dynamic and competitive. Multiple entities, including pharmaceutical companies, academic institutions, and smaller biotechnology firms, are actively seeking patent protection for novel compounds, formulations, and therapeutic strategies in this area.
Key aspects of the landscape include:
- Lysosomotropic Agents:
- Established Drugs: Many of the lysosomotropic agents mentioned in U.S. Patent 8,883,805, such as chloroquine and hydroxychloroquine, are well-established drugs with known pharmacological profiles, initially developed for other indications (e.g., malaria, autoimmune diseases). Patents in this space often focus on novel uses (repurposing), specific formulations, or combination therapies involving these agents.
- New Chemical Entities: Research continues into developing novel lysosomotropic agents with improved properties, such as better targeting, reduced off-target effects, or enhanced accumulation in specific cellular compartments.
- Antibacterial Agents:
- Novel Antibiotics: The development of new classes of antibacterial agents is a critical area of research due to rising antimicrobial resistance. Patents are filed for novel chemical structures with unique mechanisms of action.
- Repurposing and Combinations: Similar to lysosomotropic agents, existing antibacterial agents are being investigated for new uses and in combination therapies.
- Combination Therapies for Infection:
- Synergistic Effects: A significant portion of patent activity focuses on identifying and patenting combinations of agents that exhibit synergistic activity, meaning the combined effect is greater than the sum of individual effects. U.S. Patent 8,883,805 falls into this category.
- Targeting Resistance Mechanisms: Many combination therapies aim to overcome specific resistance mechanisms employed by bacteria, such as efflux pumps, enzymatic degradation of antibiotics, or alterations in drug targets.
- Broad-Spectrum vs. Targeted: Patents may cover broad combinations intended for general bacterial infections or highly specific combinations targeting particular pathogens or resistant strains.
- Formulation and Delivery: Patents also cover novel formulations and delivery systems designed to optimize the pharmacokinetics and pharmacodynamics of combination therapies, ensuring adequate concentrations reach the site of infection.
Key Players and Patenting Trends:
Major pharmaceutical companies like Pfizer, Merck, Novartis, and Gilead Sciences are active in the infectious disease patent space, both for novel antibiotics and combination strategies. Biotechnology companies often focus on niche areas, such as developing treatments for specific resistant pathogens or novel drug delivery mechanisms. Academic institutions are a significant source of early-stage research and patent filings, which are often licensed to commercial entities.
The trend is towards developing therapies that can address the growing threat of antimicrobial resistance. This includes not only novel antibiotics but also strategies that re-sensitize bacteria to existing drugs or enhance the host's immune response. Combination therapies, like that claimed in U.S. Patent 8,883,805, represent a key avenue for innovation in this field.
What Are Potential Infringement Considerations for Competitors?
Competitors seeking to develop or market pharmaceutical compositions for bacterial infections, particularly those involving Staphylococcus aureus or MRSA, must carefully consider potential infringement of U.S. Patent 8,883,805.
Key infringement considerations include:
-
Compositional Similarity: Direct infringement occurs if a competitor manufactures, uses, sells, offers for sale, or imports a pharmaceutical composition that includes:
- A lysosomotropic agent from the defined list (e.g., hydroxychloroquine, chloroquine).
- An antibacterial agent active against Staphylococcus aureus or MRSA.
- A pharmaceutically acceptable carrier.
This includes compositions where the lysosomotropic agent is present in an amount effective to increase lysosomal pH and the antibacterial agent is present in an amount effective to inhibit or kill S. aureus.
-
Method of Use: Even if a competitor develops a composition with slightly different components or ratios, indirect infringement can occur if they promote or instruct the use of their product in a manner that directly infringes the method claims. This includes:
- Treating a bacterial infection in a subject by administering a lysosomotropic agent and an antibacterial agent, where the agents achieve the described mechanism of action.
- Specifically targeting S. aureus or MRSA infections.
-
Claim Construction: The interpretation of patent claims (claim construction) is critical. Competitors will need to analyze how courts have interpreted similar claims and the specific terms used in U.S. Patent 8,883,805, such as "lysosomotropic agent," "antibacterial agent," and "effective to increase lysosomal pH."
-
Prior Art and Validity: Competitors may seek to invalidate the patent by identifying prior art that demonstrates the claimed invention was not novel or was obvious at the time of filing. However, such challenges are complex and require substantial evidence.
-
Licensing and Clearance: The most straightforward way to avoid infringement is to obtain a license from the patent holder, Alexion Pharmaceuticals, Inc. (now part of AstraZeneca). Competitors should conduct thorough freedom-to-operate (FTO) analyses to identify all relevant patents and assess their risk.
-
Scope of Antibacterial Agents: The patent claims a broad range of antibacterial agents. Competitors utilizing any of the listed classes or specific compounds in combination with a lysosomotropic agent are at a higher risk of infringement.
-
Experimental Use: While experimental use for research purposes may have some exemptions, commercialization or clinical trials without authorization generally constitute infringement.
A detailed legal and technical analysis by patent counsel is essential for any competitor considering products that fall within the scope of U.S. Patent 8,883,805.
Conclusion
U.S. Patent 8,883,805 establishes a significant claim in the area of combination therapy for bacterial infections, particularly those caused by Staphylococcus aureus and MRSA. The patent protects pharmaceutical compositions and methods that combine lysosomotropic agents with antibacterial agents to enhance the latter's intracellular delivery and efficacy. The competitive patent landscape necessitates careful consideration of infringement risks for any entity developing therapies in this domain.
Key Takeaways
- U.S. Patent 8,883,805 claims compositions and methods for treating bacterial infections by combining lysosomotropic agents with antibacterial agents.
- The primary target pathogens identified are Staphylococcus aureus and MRSA, with a proposed mechanism of action involving enhanced intracellular delivery of antibacterials.
- The patent broadly covers various classes and specific examples of lysosomotropic and antibacterial agents.
- The patent landscape is competitive, with numerous entities active in infectious disease research and patenting, particularly concerning combination therapies and antimicrobial resistance.
- Competitors must conduct thorough freedom-to-operate analyses to assess potential infringement of the patent's composition and method claims.
Frequently Asked Questions
-
What is the primary therapeutic benefit claimed for the combination therapy?
The primary benefit claimed is the enhanced efficacy of antibacterial agents against bacterial infections, specifically by increasing their intracellular concentration and delivery within host cells, leading to improved bacterial inhibition or killing.
-
Does this patent cover the use of hydroxychloroquine as a standalone treatment for bacterial infections?
No, the patent claims specifically cover the combination of a lysosomotropic agent (like hydroxychloroquine) with an antibacterial agent for treating bacterial infections. It does not claim hydroxychloroquine as a monotherapy for bacterial infections.
-
Are all bacterial infections covered by this patent?
While the claims are broad, the patent disclosures and examples heavily emphasize infections caused by Staphylococcus aureus, including MRSA. The utility is described as treating bacterial infections where the mechanism of lysosomotropic agent enhancement is applicable.
-
Who is the current assignee of U.S. Patent 8,883,805?
The original assignee was Alexion Pharmaceuticals, Inc. Alexion was acquired by AstraZeneca in 2021. Therefore, AstraZeneca is the current ultimate owner of rights related to this patent.
-
Can a competitor use chloroquine with an antibacterial agent to treat Staphylococcus aureus infections without infringing the patent?
Using chloroquine (a claimed lysosomotropic agent) in combination with an antibacterial agent to treat Staphylococcus aureus infections would likely constitute infringement of the patent's composition and method claims, unless a license is obtained or the patent is successfully challenged on grounds of invalidity.
Citations
[1] U.S. Patent No. 8,883,805 (Nov. 10, 2014).
More… ↓
⤷ Start Trial
|
